STAT1 and diabetic retinopathy: Intravenous administration of HucMSC-derived EVs in mice with diabetic retinopathy (DR) showed improved inflammatory response and reduced oxidative damage through the miR-17-3p-mediated targeting of signal transducer and activator of transcription 1 (STAT1) [21].